Arbutus to Present TKM-HBV Data at the 2015 AASLD Liver Meeting
October 01 2015 - 10:00AM
Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading
therapeutic solutions company focused on developing a cure for
chronic hepatitis B virus infection (HBV), today announced
presentation of data at the 2015 American Association for the Study
of Liver Diseases (AASLD) Liver Meeting being held on November 13 –
17, 2015, at the Moscone West Convention Center, San Francisco.
"We are encouraged by the supportive data generated for TKM-
HBV, our lead HBV clinical candidate, and are focused on advancing
the development of this product as well as our other HBV
candidates," said Dr. Mark J. Murray, Arbutus' President and CEO.
"Our preclinical data support reduction of hepatitis B surface
antigen (HBsAg) by TKM-HBV, as well as complementary effects when
combined with currently approved nucleos(t)ide analogs."
Presentation Information
and Abstract Summaries: |
|
|
Session: |
Hepatitis B: Treatment |
Date: |
November 17, 2015 |
Time: |
8.00am – 12.00pm (PT) /11.00am –3.00pm
(ET) |
- Abstract #1: "TKM-HBV, a Novel RNA Interference Treatment for
Chronic Hepatitis B, Rapidly Reduces Surface Antigen and other
Viral Proteins in Both Intrahepatic and Peripheral
Compartments"
Summary: TKM-HBV effectively removed viral antigens from both
the intrahepatic and peripheral compartments within days after
treatment initiation in hydrodynamic injection (HDI) mice. These
viral elements include immunomodulatory surface and core proteins
which are implicated in mediating the immune-repressed condition of
chronic HBV infection.
- Abstract #2: "TKM-HBV, a Novel RNA Interference Treatment for
Chronic Hepatitis B, has a Complementary Mode of Action to Current
Standard of Care Nucleos(t)ide Analogs"
Summary: Results show that TKM-HBV and nucleos(t)ide analog
modes of action are complementary, and combination therapy allows
effective disease targeting at multiple critical nodes of the viral
life cycle.
- Abstract #3: "Development of a Direct RNA Interference Therapy
for Hepatitis Delta Virus Infection"
Summary: A direct hepatitis delta virus (HDV)-targeted
siRNA-LNP approach can effectively suppress positive and negative
strand HDV RNAs and hepatitis D antigen (HDAg) protein in vitro,
and provides a promising novel strategy to treat HDV infection. The
efficacy of direct HDV targeting relative to indirect effects from
HBV gene silencing are currently under investigation.
About TKM-HBV
The goal of TKM-HBV is to facilitate HBsAg loss in patients with
chronic hepatitis B. The continued presence of HBsAg in chronic HBV
is believed to be responsible for disease pathogenesis and
impairing the body's ability to clear the virus. Blocking HBsAg may
lead to a functional cure by promoting immune-mediated clearance
and control of HBV, potentially through HBsAg seroconversion.
TKM-HBV is a novel lipid nanoparticle (LNP) formulated RNAi therapy
that uniquely targets three highly conserved regions of the HBV
viral genome. Targeting multiple sites on the HBV genome allows for
potent reduction of multiple viral antigens, knockdown across a
broad range of HBV genotypes, and a decrease in the probability of
developing antiviral resistance. Preclinical studies with TKM-HBV
have shown reductions of HBsAg and other important viral markers
across the most prevalent HBV genotypes, demonstrating that TKM-HBV
has the potential to treat patients with chronic HBV.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company
dedicated to discovering, developing and commercializing a cure for
patients suffering from chronic hepatitis B infection (HBV). Our
strategy is to target the three pillars necessary to develop a
curative regimen for HBV: suppressing HBV replication within liver
cells, stimulating and reactivating the body's immune system so
that it can mount an effective defense against the virus and,
eliminating the reservoir of viral genomic material known as
covalently closed circular DNA, or cccDNA that is the source of HBV
persistence. Our portfolio of assets includes a broad pipeline of
drug candidates for use in combination to develop a cure for HBV.
To support continuous discovery of potential novel drug candidates
and technologies, Arbutus has a research collaboration agreement
with the Baruch S. Blumberg Institute that provides exclusive
rights to in-license any intellectual property generated through
the relationship. The Baruch S. Blumberg Institute was established
in 2003 by the Hepatitis B Foundation.
Arbutus is headquartered in Vancouver, BC, Canada with offices
in Doylestown, PA, USA. For more information, visit
www.arbutusbio.com.
CONTACT: Investors
Adam Cutler
Senior Vice President, Corporate Affairs
Phone: 604.419.3200
Email: acutler@arbutusbio.com
Helia Baradarani
Manager, Investor Relations
Phone: 604.419.3200
Email: hbaradarani@arbutusbio.com
Media
Please direct all media inquiries to: media@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Sep 2023 to Sep 2024